All Articles
Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›
With the release of the final rule of the Medicare Access and CHIP Reauthorization Act (MACRA), participating providers will now be reimbursed by the Centers for Medicare & Medicaid Services (CMS) based on the quality of the care they provide rather than on the volume. Read More ›
The Oncology Care Model (OCM) is a physician-led specialty care model that is aimed at providing higher quality, more highly coordinated oncology care at the same or lower cost to Medicare beneficiaries. Read More ›
he cost of cancer care is rising quickly, and, as a result, oncology is moving away from the fee-for-service payment model toward the Oncology Care Model (OCM). Read More ›